We present a clinical scale method for immunomagnetic separation of CD56 ϩ ; isolation; immunomagnetic separation; DLI; mismatched transplantation Transplantation of highly purified CD34 ϩ stem cells from mismatched related and (partially) matched unrelated donors is now a well established method in children with high risk or relapsed leukemias who otherwise lack an HLA-identical family donor. This procedure minimizes graft-versus-host disease (GVHD) without an increased risk of graft failure. However, relapses still remain a major Correspondence: Dr P Lang, Children
problem after successful transplantation. [1] [2] [3] Donor lymphocyte infusion without alloreactivity may be an approach to control minimal residual disease early after transplantation. Several studies have shown that donor lymphocyte infusions are beneficial in relapsed patients with CML. 4, 5 The graft-versus-leukemia (GVL) effect in these cases is predominantly mediated by T cells and may be due to the alloreactive capacity rather than to specific cytotoxic T cell clones. However, the GVL effect remains less clear in ALL and AML and may be expected only in molecular relapse, which is only detectable by high sensitivity polymerase chain reaction techniques. 6 Furthermore, the use of T cell infusions is correlated with the risk of inducing severe GVHD. [7] [8] [9] Particularly in mismatched donors, severe GVHD was observed after DLI and could not be predicted even when very low cell numbers were administered. 2 In this setting, a population of effector cells is needed which provides antileukemic capacity without any risk of GVHD. Natural killer cells are known to lyse several types of malignant cells in correlation with the degree of HLA class I expression. Cells with reduced expression of HLA class I, including solid tumors, lymphomas and leukemias have been shown to be valid targets for NK cells in particular. 10, 11 Furthermore, recent work has demonstrated NK cells exerting alloreactivity after mismatched haploidentical transplantations due to an incompatibility between killer cell inhibitory receptors of donor NK cells and the recipients HLA C type. 12 However, there is no existing evidence for NK-mediated GVHD in humans so far. Thus, highly purified donor NK cells may represent a putative population of anti-leukemic effector cells for infusion within the first month after transplantation of T cell-depleted CD34 ϩ stem cells. This would provide temporary protection until hematopoetic recovery of donor-derived NK cell starts. In this study, we describe a method for rapid clinical scale selection, which can be easily adapted to GMP conditions, resulting in highly purified NK cells and maximal depletion of contaminating T cells. Functionality of the enriched cells was tested against several targets and GVHD potential was ruled out by mixed lymphocyte cultures. The depletion factor of CD3 ϩ T cells was calculated as: total number of CD3 ϩ cells in the initial fraction/total number of CD3 ϩ cells in the enriched fraction.
Materials and methods

Cytotoxicity assay
Cytolytic activity of NK cells was tested in a 2 h BATDA Europium release assay before and after each separation step. K562 (MHC class I-negative erythroleukemia cell line), BV173 (MHC class I-positive pre-B cell leukemia) and cryopreserved CD10 ϩ /CD19 ϩ leukemic blasts (common ALL) of our pediatric patients were used as targets.
Effector cells were stored overnight at 37°C in RPMI 1640ϩ10% AB serum with and without 1000IE IL-2. Target cells were labeled with the fluorescence-enhancing ligand BATDA (Wallac Oy, Turku, Finland) for 30 min (K562) or 60 min (leukemic blasts), washed five times in medium, and placed in 96-well round-bottom plates at 5000 cells per well. Effector cells were added at ratios from 40:1 to 2.5:1, in triplicates. After incubation, plates were centrifuged (200 g, 5 min) and 20 l of supernatant removed from each well and mixed with 200 l DELFIA Europium Solution (Wallac Oy). NK cell activity was quantified by measuring the intense fluorescence of the Europium TDA chelates using a time-resolved fluorometer (VICTOR from Wallac Oy).
Antibody-dependent cellular cytotoxicity (ADCC) was carried out by incubating the target cells with a humanized
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Specific lysis was calculated as follows: % specific lysis = (experimental release Ϫ spontaneous release)/(maximum release Ϫ spontaneous release) ϫ 100.
Mixed lymphocyte culture and mitogen assay
Anti-host proliferative capacity and response to phytohemagglutinin (PHA-M from Sigma-Aldrich, Taufkirchen, Germany) was measured as triplicates prior to and after each separation step: 5 ϫ 10 4 responder cells/round-bottom well were coincubated with 5 ϫ 10 4 irradiated stimulator cells (3000 cGy) from HLA mismatched healthy volunteers for 5 days. Moreover, cells were stimulated with PHA-M and with IL-2 (1000 U/ml). Cells were pulsed with 
Results
Six laboratory scale and four clinical scale experiments were carried out.
Purity and recovery of NK cells
Results are shown in Table 1 -fold (4.56 log). A representative FACS analysis of the procedure is shown in Figure 1 .
Viability of enriched CD56 ϩ CD3 Ϫ cells, determined by Trypan blue staining, remained over 90% in all separation systems. No microbial contamination was detected in the target cells.
Mixed lymphocyte cultures and mitogen stimulation
Proliferative capacity of the remaining T cells was measured by PHA stimulation, with IL-2 stimulation of NK cells as a positive control. In the presence of PHA, counts were reduced to 3.2% (Ϯ3%) of the initial sample after step 1 and to 0.8% (Ϯ1%) after step 2, whereas IL-2 stimulation of NK cells was maintained after separation (counts with 
Cytotoxicity assays
Cytotoxic activity of separated cells was measured with and without IL-2 stimulation against K562, BV173 and against fresh leukemic blasts with varying expression of HLA class I. In addition, ADCC was also investigated. The specific lysis of MNC prior to isolation and enriched NK cells after steps 1 and 2 are shown against K562 in Figure 3 . After step 1 a clear increase was observed with maximum levels after step 2. NK activity could be further enhanced by IL-2 stimulation in all experiments (data not shown). Figure  4 shows the NK activity against BV173; purified NK cells without IL-2 stimulation did not exert any lysis, but weak lysis was seen following IL-2 stimulation. A remarkable increase was observed, using a humanized anti-CD19 antibody for ADCC of unstimulated NK cells. Maximal lysis occurred with a combination of IL-2 stimulation and ADCC. Cytotoxic activity was further measured against fresh leukemic blasts (pre-B cell leukemias) with low and high HLA class I expression. Leukemic blasts with low HLA class I were lysed even by non-stimulated NK cells. IL-2 activation resulted in a more efficient lysis of the blasts, which was further enhanced by preincubation with anti-CD19 ( Figure 5 ). In contrast, both non-stimulated and activated NK cells failed to lyse blasts with high HLA class I expression. However, ADCC with anti-CD19 preincubation was again highly effective ( Figure 6 ). Possible complement-mediated cytotoxicity or cytotoxic effects of the antibody in all ADCC experiments were ruled out by incubation of target cells with no effector cells present (specific lysis Ͻ5%).
Discussion
The effects of adoptively transferred NK cells in the autologous setting have already been investigated in various clinical studies, showing a limited benefit in patients with high tumor burden. [13] [14] [15] It has been shown in the mouse model, that adoptive transfer of donor NK cells can induce antileukemic effects without inducing GVHD 16 and prevention of GVHD has even been reported. 17 However, there remain little data regarding infusion of allogeneic NK cells in relapsed patients after transplantation 18, 19 and, to our knowledge, treatment of minimal residual disease has not been evaluated at all. 
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The induction of severe GVHD has emerged as a major risk factor in the use of lymphocyte infusions from unrelated or mismatched (haploidentical) family donors. Unfortunately, pre-existing separation methods have rather neglected the role of contaminating T cells, 20 which may lead to severe side-effects in this situation.
Thus, our aim has been to establish a clinical scale procedure, that offers both high purity of functional NK cells with maximal depletion of T cells. We have demonstrated in preliminary laboratory scale experiments that positive selection of CD56 ϩ cells with the MACS method (Vario MACS) followed by depletion of contaminating CD3 ϩ cells with Dyna beads provides a suitable combinatorial approach. Because CD56 ϩ cells were already coated with magnetic beads in the first step, the same procedure could not be used for the second. Depletion of T cells with Dyna beads did not affect the precoated CD56 ϩ cells due to the small size of the MACS beads and insufficient magnetization for being retained in the weak magnetic field used for Dyna bead selection. Consequently, only 10% of the target cells obtained from step 1 were lost in the second step.
For clinical scale experiments, leukaphereses from unmobilized healthy donors were processed with the CLIN-IMACS, yielding a recovery of 56% with 15.8% contaminant CD3 ϩ CD56 Ϫ T cells, which was considered to be insufficiently pure for our purpose. However, the second step resulted in a profound depletion of CD3 ϩ cells with Ͻ0.01% contaminant CD3 ϩ CD56 Ϫ T cells and 0.09% CD3 ϩ
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ϩ NK-T cells. With such a profound T cell depletion, the rather low recovery of 40% appears to be acceptable. In our experience, a threshold of 25 000 contaminating T cells per kg bodyweight should not be exceeded in the graft or in DLI. Thus, a content of 0.1% T cells would allow the infusion of a maximum of 25 ϫ 10 6 /kg purified NK cells. In the case of a 20 kg pediatric patient, a 1 h leukapheresis would provide enough leukocytes for infusion of up to 10 ϫ 10 6 NK cells/kg. In order to maintain antileukemic activity until hematopoietic recovery of CD34 ϩ -derived NK cells starts, several infusions (days 0, 7, 14) may be beneficial.
The time needed for the separation procedure was about 4 h, proving it to be time saving and uncomplicated. As an advantage, the protocol can be carried out within a day, including a 1-3 h leukapheresis. Only small amounts of antibody-coated beads are needed, due to the combination of positive selection in the first and negative depletion in the second step. Furthermore, the procedure can be adapted to GMP conditions without changing the separation strategy by the use of GMP grade beads instead of research grade material. Since parts of the separation were not carried out in a closed system, a clean room facility is required.
The efficacy of T cell depletion was also demonstrated in functional assays. T cell response to PHA stimulation was reduced to 0.8% of the initial sample and the anti-host proliferative potential was shown to be minimized in the MLC. Based on these findings, we suggest the risk of inducing GVHD is significantly reduced.
NK activity against K562 target cells was remarkably increased after the separation procedure and also fresh leukemic blasts with low HLA class I expression were suf-ficiently lysed. In contrast, even purified NK cells were ineffective against targets with high HLA expression (BV173 and other fresh leukemic blasts). This inhibition correlates with the expression of killer cell inhibitory receptors on NK cells which recognize several HLA class I alleles, in particular HLA C. Depending on the expression type and distribution of its KIRs a particular NK cell can be inhibited by specific HLA ligands of the target cell. 12 Moreover, inactivation of a mixture of NK cells expressing several different KIRs is not only dependent on specific HLA alleles but also correlates with the total number of HLA molecules. However, this KIR inhibition could be overcome by deploying antibody-dependent cellular cytotoxicity; pre-incubation of target cells with a humanized anti-CD19 antibody enabled NK cells to bind via Fc gamma receptor resulting in a strong lysis of target cells even with high HLA class I expression. Therefore, a combinatorial approach (donor NK cells, application of IL-2, use of appropriate antibodies such as anti-CD19 for pre-B ALL) results in further enhancement of cytotoxic activity in vitro and might also be considered as an immunotherapeutic strategy for the treatment of MRD in vivo.
In conclusion, the method described allows procurement of NK cells with extremely low T cell content and potential antileukemic activity. We suppose that those cells may be used for DLI early after allogeneic transplantation with minimal risk of inducing severe GVHD, especially in the case of mismatched donors. Moreover, NK infusions at day 0 might promote engraftment of CD34 ϩ cells, as shown in the mouse model. 21 Thus, further clinical studies have to be done to evaluate the role of donor NK cell infusions in the treatment of MRD after transplantation of CD34 ϩ stem cells from unrelated or mismatched family donors.
